Capital International Inc. CA Purchases 14,444 Shares of CVS Health Corporation $CVS

Capital International Inc. CA increased its stake in shares of CVS Health Corporation (NYSE:CVS) by 1.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 867,134 shares of the pharmacy operator’s stock after acquiring an additional 14,444 shares during the quarter. Capital International Inc. CA’s holdings in CVS Health were worth $68,816,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Kingsview Wealth Management LLC raised its stake in CVS Health by 316.2% during the third quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after purchasing an additional 79,340 shares in the last quarter. Intech Investment Management LLC raised its stake in CVS Health by 50.3% during the third quarter. Intech Investment Management LLC now owns 86,564 shares of the pharmacy operator’s stock valued at $6,526,000 after purchasing an additional 28,953 shares in the last quarter. Assetmark Inc. raised its stake in CVS Health by 12.5% during the third quarter. Assetmark Inc. now owns 678,558 shares of the pharmacy operator’s stock valued at $51,156,000 after purchasing an additional 75,603 shares in the last quarter. Hamlin Capital Management LLC purchased a new stake in CVS Health during the fourth quarter valued at $160,844,000. Finally, Cresset Asset Management LLC raised its stake in CVS Health by 56.8% during the third quarter. Cresset Asset Management LLC now owns 35,481 shares of the pharmacy operator’s stock valued at $2,675,000 after purchasing an additional 12,849 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on CVS shares. Mizuho upped their price target on shares of CVS Health from $102.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, May 20th. Deutsche Bank Aktiengesellschaft upped their price target on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Barclays upped their price target on shares of CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. UBS Group upped their price target on shares of CVS Health from $97.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada upped their price target on shares of CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $99.88.

Insider Activity

In related news, Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This trade represents a 24.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,441,551 shares of company stock worth $323,703,977 in the last ninety days. 0.85% of the stock is currently owned by insiders.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health was upgraded to a Zacks Rank #2 (Buy), reflecting improved earnings optimism and adding to the bullish tone around the stock. Article Title
• Positive Sentiment: Broker sentiment remains constructive on CVS Health, with recent coverage pointing to favorable views from Wall Street analysts and broader confidence in the company’s outlook. Article Title
• Positive Sentiment: The managed-care group rallied after analysts cited softer medical cost and utilization trends across the sector, which can support margins and spill over positively to CVS Health. Article Title
• Neutral Sentiment: CVS Health highlighted community and affordable-housing projects in New Jersey and Massachusetts, underscoring its corporate social responsibility efforts, but these announcements are unlikely to move the stock materially. Article Title
• Neutral Sentiment: Media coverage noted CVS Health is up about 8.5% since its last earnings report and asked whether the rally can continue, mainly reflecting investor attention on post-earnings momentum rather than a new catalyst. Article Title
• Neutral Sentiment: CVS CEO comments on AI, “super apps,” and primary care suggest longer-term strategy focus, but there was no immediate financial update in the coverage. Article Title
• Neutral Sentiment: Additional community partnership news, including a job training lab in Lincoln Heights, is supportive of the brand but not a direct earnings driver. Article Title

CVS Health Trading Up 1.4%

Shares of CVS opened at $96.11 on Friday. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $98.43. The company has a market cap of $122.62 billion, a P/E ratio of 42.34, a P/E/G ratio of 0.94 and a beta of 0.62. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The company’s fifty day simple moving average is $84.13 and its 200-day simple moving average is $80.03.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the prior year, the firm posted $2.25 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, analysts expect that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.